[go: up one dir, main page]

SG10202101830WA - Processes for preparing oligomers - Google Patents

Processes for preparing oligomers

Info

Publication number
SG10202101830WA
SG10202101830WA SG10202101830WA SG10202101830WA SG10202101830WA SG 10202101830W A SG10202101830W A SG 10202101830WA SG 10202101830W A SG10202101830W A SG 10202101830WA SG 10202101830W A SG10202101830W A SG 10202101830WA SG 10202101830W A SG10202101830W A SG 10202101830WA
Authority
SG
Singapore
Prior art keywords
processes
preparing oligomers
oligomers
preparing
Prior art date
Application number
SG10202101830WA
Other languages
English (en)
Inventor
Bao Cai
Mitchell Martini
Ross Shimabuku
Katie Thomas
Diane Elizabeth Frank
Richard K Bestwick
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of SG10202101830WA publication Critical patent/SG10202101830WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
SG10202101830WA 2016-05-24 2017-05-24 Processes for preparing oligomers SG10202101830WA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662341049P 2016-05-24 2016-05-24
US201662357153P 2016-06-30 2016-06-30
US201662356923P 2016-06-30 2016-06-30
US201662357072P 2016-06-30 2016-06-30
US201662357166P 2016-06-30 2016-06-30
US201762508256P 2017-05-18 2017-05-18

Publications (1)

Publication Number Publication Date
SG10202101830WA true SG10202101830WA (en) 2021-04-29

Family

ID=59078165

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202101830WA SG10202101830WA (en) 2016-05-24 2017-05-24 Processes for preparing oligomers

Country Status (21)

Country Link
US (2) US10875880B2 (da)
EP (2) EP3464305B1 (da)
JP (2) JP7008642B2 (da)
KR (1) KR102506298B1 (da)
CN (1) CN109563114B (da)
AU (1) AU2017269355B2 (da)
BR (2) BR112018074346B1 (da)
CA (1) CA3025339A1 (da)
CO (1) CO2018013838A2 (da)
DK (1) DK3464305T3 (da)
ES (1) ES2993738T3 (da)
FI (1) FI3464305T3 (da)
HR (1) HRP20241428T1 (da)
IL (1) IL263149B2 (da)
MA (2) MA45154B1 (da)
MD (1) MD3464305T2 (da)
MX (2) MX384727B (da)
SA (1) SA518400500B1 (da)
SG (1) SG10202101830WA (da)
TW (2) TWI738784B (da)
WO (1) WO2017205496A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
BR112018074346B1 (pt) 2016-05-24 2023-01-03 Sarepta Therapeutics, Inc. Composto oligomérico e processo para preparar um composto oligomérico
SG11201809499UA (en) * 2016-05-24 2018-12-28 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
IL263044B2 (en) 2016-05-24 2024-06-01 Sarepta Therapeutics Inc Processes for the preparation of phosphorodiamidate morpholino oligomers
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
CN109152775B (zh) * 2016-06-30 2022-04-26 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
JP7022079B2 (ja) * 2016-06-30 2022-02-17 サレプタ セラピューティクス, インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
MA49986A (fr) * 2017-09-25 2020-07-01 Massachusetts Inst Technology Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
US20210102205A1 (en) * 2018-04-26 2021-04-08 Sarepta Therapeutics, Inc. Exon skipping oligomers and oligomer conjugates for muscular dystrophy
WO2024163762A2 (en) * 2023-02-01 2024-08-08 Alnylam Pharmaceuticals, Inc. Six membered ring containing oligomers

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
DE3687030T2 (de) 1985-03-15 1993-03-11 Eugene Stirchak Stereoregulare polynukleotiden bindende polymere.
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
AU4225889A (en) 1988-09-01 1990-04-02 Forskningscenter Riso Peptide synthesis method and solid support for use in the method
KR100386542B1 (ko) 1993-12-29 2003-10-11 후지사와 야꾸힝 고교 가부시키가이샤 피라졸로피리딘아데노신길항제
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
DE60033927T2 (de) 1999-05-04 2007-11-29 Santaris Pharma A/S L-ribo-lna analoge
JP2003533986A (ja) 2000-05-04 2003-11-18 エイブイアイ バイオファーマ, インコーポレイテッド スプライス領域アンチセンス組成物および方法
WO2003020739A2 (en) 2001-09-04 2003-03-13 Exiqon A/S Novel lna compositions and uses thereof
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
CA2504554A1 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. 2'-substituted oligomeric compounds and compositions for use in gene modulations
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
EP3228711A1 (en) 2004-06-28 2017-10-11 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
HUE036995T2 (hu) * 2006-05-10 2018-08-28 Sarepta Therapeutics Inc Az alegységek között kationos kötéssel rendelkezõ oligonukleotid analógok
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
CN101861318A (zh) 2007-11-15 2010-10-13 Avi生物制药公司 合成吗啉代低聚物的方法
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
EP2350281B1 (en) 2008-10-24 2014-05-14 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
HUE028036T2 (en) 2009-04-10 2016-11-28 Ass Inst De Myologie Tricyclic DNA anti-sense oligonucleotides, compositions and methods for treating a disease
NZ716534A (en) 2009-11-12 2018-06-29 Univ Western Australia Antisense molecules and methods for treating pathologies
TWI463423B (zh) * 2010-05-28 2014-12-01 Poynt Corp 用以針對基於三維形狀之廣告系統使用位置資訊的方法
KR102182663B1 (ko) * 2010-05-28 2020-11-25 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
SMT201700038T1 (it) 2010-09-30 2017-03-08 Nippon Shinyaku Co Ltd Derivati morfolinici di acidi nucleici
US9078911B2 (en) * 2011-02-08 2015-07-14 The Charlotte-Mecklenburg Hospital Authority Antisense oligonucleotides
WO2013026142A1 (en) 2011-08-23 2013-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University Ionic tags for synthesis of oligoribonucleotides
DK2581448T3 (da) 2011-10-13 2015-04-27 Ass Inst De Myologie Tricyclo-phosphorothioat-DNA
HK1201514A1 (en) 2011-11-18 2015-09-04 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
ES2727481T3 (es) * 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Inclusión inducida de exón en atrofia muscular espinal
CN108588073A (zh) * 2011-12-28 2018-09-28 日本新药株式会社 反义核酸
ES2741099T3 (es) 2012-02-28 2020-02-10 Agilent Technologies Inc Método de fijación de una secuencia de recuento para una muestra de ácido nucleico
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
US20140329881A1 (en) * 2013-03-14 2014-11-06 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
BR112015023038A2 (pt) * 2013-03-14 2017-11-14 Sarepta Therapeutics Inc composições para salto de exon para o tratamento da distrofia muscular
CN113633787A (zh) 2013-03-15 2021-11-12 萨勒普塔医疗公司 改进的用于治疗肌营养不良的组合物
CN105228999B (zh) * 2013-05-24 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
BR112018074346B1 (pt) 2016-05-24 2023-01-03 Sarepta Therapeutics, Inc. Composto oligomérico e processo para preparar um composto oligomérico
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
SG11201809499UA (en) * 2016-05-24 2018-12-28 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
IL263044B2 (en) 2016-05-24 2024-06-01 Sarepta Therapeutics Inc Processes for the preparation of phosphorodiamidate morpholino oligomers
ES2927079T3 (es) 2016-12-19 2022-11-02 Sarepta Therapeutics Inc Conjugados de oligómero de omisión de exones para distrofia muscular
CN110636866B (zh) 2016-12-19 2024-10-18 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
NZ755422A (en) 2016-12-19 2023-06-30 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии

Also Published As

Publication number Publication date
FI3464305T3 (fi) 2024-10-30
EP3464305A1 (en) 2019-04-10
IL263149B1 (en) 2023-01-01
EP3464305B1 (en) 2024-08-21
IL263149B2 (en) 2023-05-01
CN109563114A (zh) 2019-04-02
ES2993738T3 (en) 2025-01-08
JP7008642B2 (ja) 2022-01-25
IL263149A (en) 2019-01-31
US20200040020A1 (en) 2020-02-06
HRP20241428T1 (hr) 2025-01-03
AU2017269355A1 (en) 2019-01-17
BR122022014984B1 (pt) 2024-03-05
US11384105B2 (en) 2022-07-12
CA3025339A1 (en) 2017-11-30
JP2019518832A (ja) 2019-07-04
BR112018074346B1 (pt) 2023-01-03
TW202200599A (zh) 2022-01-01
JP2021176967A (ja) 2021-11-11
KR20190015311A (ko) 2019-02-13
DK3464305T3 (da) 2024-10-28
TWI801843B (zh) 2023-05-11
CO2018013838A2 (es) 2019-01-18
MX2021008539A (es) 2022-10-18
BR112018074346A2 (pt) 2019-03-06
EP3564248A1 (en) 2019-11-06
KR102506298B1 (ko) 2023-03-06
MA49775A (fr) 2020-06-10
MD3464305T2 (ro) 2025-01-31
SA518400500B1 (ar) 2022-09-01
CN109563114B (zh) 2022-08-12
US10875880B2 (en) 2020-12-29
MA45154B1 (fr) 2024-11-29
MA45154A (fr) 2019-04-10
WO2017205496A1 (en) 2017-11-30
TW201806962A (zh) 2018-03-01
AU2017269355B2 (en) 2021-04-15
MX384727B (es) 2025-03-14
US20210198296A1 (en) 2021-07-01
TWI738784B (zh) 2021-09-11
MX2018014472A (es) 2019-05-23

Similar Documents

Publication Publication Date Title
IL263149A (en) Processes for the preparation of oligomers
ZA201708142B (en) Process for preparing 4-amino-pyridazines
IL248960A0 (en) Processes for preparing antiviral compounds
HUE059158T2 (hu) Eljárás pridopidin elõállítására
IL274439A (en) Process for making Tapinaroff
IL252912A0 (en) Processes for preparing oxathiazine-like compounds
PT3371150T (pt) Processo de preparação do brivaracetam
PL3548473T3 (pl) Sposób wytwarzania hmf
GB201807019D0 (en) Locking apparatus
ZA201706505B (en) Processes for preparing fluoroketolides
IL253877A0 (en) Process for preparing 3-chloro-2-vinylphenylsulfonates
HUE054626T2 (hu) Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
ZA201903463B (en) Method for preparing hexadecahydropyrene
ZA201908452B (en) Improved process for preparing imetelstat
IL249283A0 (en) Process for the preparation of 3-chloro-2-vinylphenol
TWI560352B (en) Locking apparatus
HK40005805B (en) Processes for preparing oligomers
ZA201807441B (en) Process for preparing oxathiazin-like compounds